Botox therapy for ischemic digits

Michael W Neumeister, Christopher B Chambers, Margo S Herron, Kelli Webb, Joel Wietfeldt, Jessica N Gillespie, Rueben A Bueno Jr, Carisa M Cooney, Michael W Neumeister, Christopher B Chambers, Margo S Herron, Kelli Webb, Joel Wietfeldt, Jessica N Gillespie, Rueben A Bueno Jr, Carisa M Cooney

Abstract

Background: Treating patients with Raynaud's phenomenon who have chronic pain and ulcerations is extremely challenging. Unrelenting pain can lead to dysfunction and disuse, rendering the patient debilitated and/or chronically depressed. Pharmacologic vasodilators and surgical sympathectomies offer variable benefits. Outcomes of symptomatic patients treated with botulinum toxin type A (Botox) injections for Raynaud's phenomenon are presented.

Methods: A retrospective study focused on patient outcomes was performed on 19 patients diagnosed with Raynaud's phenomenon. Patients suffered from chronic ischemic hand pain. All patients had vascular studies to rule out occlusive disease. Fifty to 100 units of Botox were injected into the palm around each involved neurovascular bundle. Preinjection and postinjection laser Doppler scanning was performed on most patients to measure blood flow.

Results: Sixteen of 19 patients (84 percent) reported pain reduction at rest. Thirteen patients reported immediate relief; three reported more gradual pain reduction over 1 to 2 months. Three patients had no or minimal pain relief. Tissue perfusion results demonstrated a marked change in blood flow (-48.15 percent to 425 percent) to the digits. All patients with chronic finger ulcers healed within 60 days. Most patients [n = 12 (63 percent)] remained pain-free (13 to 59 months) with a single-injection schedule. Four patients (21 percent) required repeated injections because of recurrent pain.

Conclusions: Vascular function is abnormal in patients with Raynaud's phenomenon. Although its mechanism is unknown, Botox yielded a distinct improvement in perfusion and reduction in pain in patients failing conservative management. Continued research may lead to more specific and reliable treatment for Raynaud's patients.

References

    1. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: A meta-analysis. Rheumatology 2005;44:145–150.
    1. Plante GE. Depression and cardiovascular disease: A reciprocal relationship. Metabolism 2005:54(5 Suppl 1):45–48.
    1. Nihtgyanova SI, Brough GM, Black CM, Denton CP. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2008;67:120–123.
    1. Kotsis SV, Chung KC. A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia. J Rheumatol. 2003;30:1788–1792.
    1. Zang WW, Harris LM, Shenoy SS, Hassett JM, Wall LP. Outcomes of patients with atherosclerotic upper extremity tissue loss. Vasc Endovasc Surg. 2005;39:33–38.
    1. Bogoch ER, Gross DK. Surgery of the hand in patients with systemic sclerosis: Outcomes and considerations. J Rheumatol. 2005;32:642–648.
    1. Ortensi A, Salsano F, Trinchi S, D'orazi V, Pisarri S. Microsurgical distal sympathectomy in chronic vasospastic syndromes of the hand. Int Surg. 2005;90:88–92.
    1. Agarwal J, Azchary L. Digital sympathectomy of the lower extremity: A novel approach to toe salvage. Plast Reconstr Surg. 2005;116:1098–1102.
    1. Wang WH, Lai CS, Chang KP, et al. Peripheral sympathectomy for Raynaud's phenomenon: A salvage procedure. Kaohsiung J Med Sci. 2006;22:491–499.
    1. Flattg AE. Digital artery sympathectomy. J Hand Surg (Am.) 1980;5:550–556.
    1. McCall TE, Petersen DP, Wong LB. The use of digital artery sympathectomy as a salvage procedure for severe ischemia of Raynaud's disease and phenomenon. J Hand Surg (Am.) 1999;24:173–177.
    1. Sycha T, Graninger M, Auff E, Schnider P. Botulinum toxin in the treatment of Raynaud's phenomenon: A pilot study. Eur J Clin Invest. 2004;34:312–313.
    1. Van Beek AL, Lim PK, Gear AJL, Pritzker MR. Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg. 2007;119:217–226.
    1. Koman LARD, Smith BP, Smith TL. Vascular disorders. In: Green DP, Hotchkiss RN, Pederson WC, eds. Green's Operative Hand Surgery. New York: Churchill Livingstone; 1999:2254–2302.
    1. Coffman JD. Raynaud's phenomenon. Curr Treat Options Cardiovasc Med. 2000;2:219–226.
    1. Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology 2005;44:587–596.
    1. Herrick AL. Vascular function in systemic sclerosis. Curr Opin Rheumatol. 2000;12:527–533.
    1. Bakst R, Merola JF, Franks AG Jr, Sanchez M. Raynaud's phenomenon: Pathogenesis and management. J Am Acad Dermatol. 2008;59:633–653.
    1. Edwards CM, Marshall JM, Pugh M. Cardiovascular responses evoked mild cool stimuli in primary Raynaud's disease: The role of endothelin. Clin Sci (Lond.) 1999;96:577–588.
    1. Bedarida GV, Kim D, Blaschke TF, Hoffman BB. Venodilation in Raynaud's disease. Lancet 1993;342:1451–1454.
    1. Leppert J, Ringqvist A, Ahlner J, et al. Seasonal variations in cyclic GMP response on whole-body cooling in women with primary Raynaud's phenomenon. Clin Sci. 1997;93:175–179.
    1. Yaksh TL, Chaplan SR. Physiology and pharmacology of neuropathic pain. Anesthesiol Clin N Am. 1997;15:335–353.
    1. Schiano TD, Parkman HP, Miller LS, Dabezies MA, Cohen S, Fisher RS. Use of botulinum toxin in the treatment of achalasia. Dig Dis. 1998;16:14–22.
    1. Tsai CP, Liu CY, Lin KP, Wang KC. Efficacy of botulinum toxin type a in the relief of carpal tunnel syndrome: A preliminary experience. Clin Drug Invest. 2006;26:511–515.
    1. Moore AP, Ade-Hall RA, Smith CT, et al. Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy. Neurology 2008;71:122–128.
    1. Dodick DW, Mauskop A, Elkind AH, et al. Botulinum toxin type a for the prophylaxis of chronic daily headache: Subgroup analysis of patients not receiving other prophylactic medications. A randomized double-blind, placebo-controlled study. Headache 2005;45:315–324.
    1. Spiegel JH. Treatment of periorbital rhytids with botulinum toxin type A: Maximizing safety and results. Arch Facial Plast Surg. 2005;7:198–202.
    1. Oeconomou A, Madersbacher H, Kiss G, Berger TJ, Melekos M, Rehder P. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. Eur Urol. 2008;54:765–777.
    1. Hecht MJ, Stolze H, Auf dem Brinke M, et al. Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia: Report of 19 cases. Mov Disord. 2008;23:228–233.
    1. Schurch B, de Sèze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196–200.
    1. Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 2004;64:871–875.
    1. Wong SM, Hui AC, Tong PY, Poon DW, Yu E, Wong LK. Treatment of lateral epicondylitis with botulinum toxin: A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2005;143:793–797.
    1. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000;40:445–450.
    1. Yoon SJ, Ho J, Kang HY, et al. Low-dose botulinum toxin type A for the treatment of refractory piriformis syndrome. Pharmacotherapy 2007;27:657–665.
    1. Lang AM. Botulinum toxin type B in piriformis syndrome. Am J Phys Med Rehabil. 2004;83:198–202.
    1. Jahangir AW, Tan HJ, Norlinah MI, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. Med J Malaysia 2007;62:319–322.
    1. Slawek J, Bogucki A, Reclawowicz D. Botulinum toxin type A for upper limb spasticity following stroke: An open-label study with individualised, flexible injection regimens. Neurol Sci. 2005;26:32–39.
    1. Salardini A, Richardson D, Jabbari B. Relief of intractable pruritus after administration of botulinum toxin A (botox): A case report. Clin Neuropharmacol. 2008;31:303–306.
    1. Klein AM, Stong BC, Wise J, DelGaudio JM, Hapner ER, Johns MM 3rd. Vocal outcome measures after bilateral posterior cricoarytenoid muscle botulinum toxin injections for abductor spasmodic dysphonia. Otolaryngol Head Neck Surg. 2008;139:421–423.
    1. Setler P. Therapeutic use of botulinum toxins: Background and history. Clin J Pain 2002;18:S119–S124.
    1. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107:125–133.
    1. Alfredson H, Lorentzon R. Chronic tendon pain: No signs of chemical inflammation but high concentrations of the neurotransmitter glutamate. Implications for treatment? Curr Drug Targets 2002;3:43–54.
    1. Devor M. Neuropathic pain and injured nerve: Peripheral mechanisms. Br Med Bull. 1991;47:619–630.
    1. Coderre TJ, Yashpal K. Intracellular messengers contributing to persistent nociception and hyperalgesia induced by L-glutamate and substance P in the rat formalin pain model. Eur J Neurosci. 1994;6:1328–1334.
    1. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000;38:245–258.
    1. Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Nippon Ganka Gakkai Zasshi 2001;105:218–222.
    1. Levine JD, Fields HL, Basbaum AI. Peptides and the primary afferent nociceptor. J Neurosci. 1993;13:2273–2286.
    1. McMahon HT, Foran P, Dolly JO, Verhage M, Wiegant VM, Nicholls DG. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes: Clues to the locus of action. J Biol Chem. 1992;267:21338–21343.
    1. Chung K, Kim HJ, Na HS, Park MJ, Chung JM. Abnormalities of sympathetic innervation in the area of an injured peripheral nerve in a rat model of neuropathic pain. Neurosci Lett. 1993;162:85–88.
    1. Devor M, Wall PD. Cross-excitation in dorsal root ganglia of nerve-injured and intact rats. J Neurophysiol. 1990;64:1733–1746.
    1. Cameron AA, Cliffer KD, Dougherty PM, Willis WD, Carlton SM. Changes in lectin, GAP-43 and neuropeptide staining in the rat superficial dorsal horn following experimental peripheral neuropathy. Neurosci Lett. 1991;131:249–252.
    1. Garrison CJ, Dougherty PM, Kajander KC, Carlton SM. Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury. Brain Res. 1991;565:1–7.
    1. Balogh B, Mayer W, Vesely M, Mayer S, Partsch H, Piza-Katzer H. Adventitial stripping of the radial and ulnar arteries in Raynaud's disease. J Hand Surg (Am.) 2002;27:1073–1080.
    1. Tomanino MM, King J, Medsger T. Rationale for and efficacy of digital arterial reconstruction in scleroderma: Report of two cases. J Reconstr Microsurg. 2002;18:263–268.
    1. Ruch DS, Holden M, Smith BP, Smith TL, Koman LA. Periarterial sympathectomy in scleroderma patients: Intermediate-term follow-up. J Hand Surg (Am.) 2002;27:258–264.
    1. Tomaino MM, Goitz RJ, Medsger TA. Surgery for ischemic pain and Raynaud's phenomenon in scleroderma: A description of treatment protocol and evaluation of results. Microsurgery 2001;21:75–79.
    1. Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: Adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53:407–415.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する